

DAFTAR PUSTAKA

1. Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. *Clin Adv Hematol Oncol*. 2015 Apr;13(4 Suppl 4):3–6.
2. Carling T, Udelsman R. Thyroid cancer. *Annu Rev Med*. 2014;65:125–37.
3. National Cancer Institute. Cancer Stat Facts: Thyroid Cancer [Internet]. 2021 [cited 2022 Mar 5]. Available from: <https://seer.cancer.gov/statfacts/html/thyro.html>
4. Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. *Front Endocrinol (Lausanne)*. 2020;11:102.
5. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. *JAMA Intern Med*. 2021;181(10):1351–8.
6. American Cancer Society. Thyroid Cancer [Internet]. American Cancer Society .2021[cited 2022 Mar 5]. Available from: <https://www.cancer.org/cancer/thyroid-cancer.html>
7. Globocan 2020. Estimated number of new cases in 2020, both sexes, all ages [Internet]. World Health Organization. 2021 [cited 2022 Apr 18]. Available from: <https://gco.iarc.fr/today/home>
8. Belladonna S. Karakteristik histopatologi karsinoma tiroid di RSUP Dr. M. Djamil Padang tahun 2014–2016. Universitas Andalas. 2017;33–9.
9. National Cancer Institute. Thyroid Cancer Treatment [Internet]. 2021 [cited 2022 Mar 5]. Available from: https://www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq#_313_toc
10. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. *Obesity reviews*. 2015;16(12):1042–54.
11. Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R, *et al*. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case–control studies. *Thyroid*. 2014;24(6):966–74.
12. Al-Hakami HA, Alqahtani R, Alahmadi A, Almutairi D, Algarni M, Alandejani T. Thyroid Nodule Size and Prediction of Cancer: A Study at Tertiary Care Hospital in Saudi Arabia. *Cureus*. 2020 Mar 30;

13. Rahimi M, Farshchian N, Rezaee E, Shahebrahimi K, Madani H. To differentiate benign from malignant thyroid nodule comparison of sonography with FNAC findings. *Pak J Med Sci*. 2012 Nov 1;29(1).
14. Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, *et al*. Thyroid Nodule Size and Prediction of Cancer. *J Clin Endocrinol Metab*. 2013 Feb;98(2):564–70.
15. Harahap RA. Karakteristik Penderita Kanker Tiroid di Rumah Sakit Haji Adam Malik Tahun 2013–2015. Universitas Sumatera Utara. 2016;35–45
16. Kuru B, Gulcelik NE, Gulcelik MA, Dincer H. The false-negative rate of fine-needle aspiration cytology for diagnosing thyroid carcinoma in thyroid nodules. *Langenbecks Arch Surg*. 2010 Feb 19;395(2):127–32.
17. El-Gammal A, E-Balshy M, Zahran K. Relationship between thyroid nodule size and incidence of thyroid cancer. *Menoufia Medical Journal*. 2019;32(3):1142.
18. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. *Nat Rev Endocrinol*. 2016;12(11):646–53.
19. Iglesias ML, Schmidt A, Ghuzlan A Al, Lacroix L, Vathaire F de, Chevillard S, *et al*. Radiation exposure and thyroid cancer: a review. *Arch Endocrinol Metab*. 2017 Mar;61(2):180–7.
20. Seib CD, Sosa JA. Evolving Understanding of the Epidemiology of Thyroid Cancer. *Endocrinol Metab Clin North Am*. 2019 Mar;48(1):23–35.
21. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. *Hum Reprod Update*. 2017 May 1;23(3):300–21.
22. Pappa T, Alevizaki M. Obesity and Thyroid Cancer: A Clinical Update. *Thyroid*. 2014 Feb;24(2):190–9.
23. Liu J, Xu T, Ma L, Chang W. Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer. *Front Oncol*. 2021 Apr 28;11.
24. Chen G, Vlantis A, Zeng Q, van Hasselt C. Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer. *Curr Cancer Drug Targets*. 2008 Aug 1;8(5):367–77.
25. Franchini F, Palatucci G, Colao A, Ungaro P, Macchia PE, Nettore IC. Obesity and Thyroid Cancer Risk: An Update. *Int J Environ Res Public Health*. 2022 Jan 20;19(3):1116.
26. Khanna D, Rehman A. Pathophysiology of Obesity [Internet]. *StatPearls* 2022. [cited 2022 Mar 9]. Available from : [https:// pubmed. ncbi. nlm. nih.gov/34283442/](https://pubmed.ncbi.nlm.nih.gov/34283442/)

27. Rehem RA, Elwafa WA, Elwafa RA, Abdel-Aziz TE. Study of Serum Leptin in Well-differentiated Thyroid Carcinoma: Correlation with Patient and Tumor Characteristics. *World J Surg*. 2014 Oct 28;38(10):2621–7.
28. Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, *et al*. The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. *J Clin Endocrinol Metab*. 2015 Dec 1;100(12):4434–40.
29. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. *Thyroid*. 2013;23(4):449–55.
30. Chng C, Tan H, Too C, Lim W, Chiam P, Zhu L, *et al*. Diagnostic performance of ATA, BTA and TIRADS sonographic patterns in the prediction of malignancy in histologically proven thyroid nodules. *Singapore Med J*. 2018 Nov;578–83.
31. Livhits MJ, Yeh MW. Rate of Nodule Growth on Surveillance Ultrasound Predicts Risk of Malignancy. *Clin Thyroidol*. 2017 Dec;29(12):465–7.
32. Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and general considerations of thyroid cancer. *Ann Clin Pathol*. 2015;3(1):1045.
33. American Thyroid Association. Thyroid Cancer (Papillary and Follicular) [Internet]. 2022 [cited 2022 Mar 9]. Available from: https://www.thyroid.org/wp-content/uploads/patients/brochures/ThyroidCancer_brochure.pdf
34. Xu bin, Wei S, Zhao X. Thyroid & parathyroid [Internet]. *PathologyOutlines*. 2023 [cited 2023 Jun 9]. Available from: <https://www.pathologyoutlines.com/topic/thyroidfollicular.html>
35. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, *et al*. RAS point mutations and PAX8-PPAR γ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. *J Clin Endocrinol Metab*. 2003;88(5):2318–26.
36. Rashid M, Agarwal A, Pradhan R, George N, Kumari N, Sabaretnam M, *et al*. Genetic alterations in anaplastic thyroid carcinoma. *Indian J Endocrinol Metab*. 2019;23(4):480.
37. Wasserman J. Medullary thyroid carcinoma [Internet]. *MyPathologyReport*. 2023 [cited 2023 Jun 9]. Available from: <https://www.mypathologyreport.ca/diagnosis-library/medullary-thyroid-carcinoma/>
38. Adham M, Aldino N. Diagnosis dan tatalaksana karsinoma tiroid berdiferensiasi. *Oto Rhino Laryngologica Indonesiana*. 2019;48(2):197–209.

39. Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. *Am Health Drug Benefits*. 2015 Feb;8(1):30–40.
40. Seib CD, Sosa JA. Evolving Understanding of the Epidemiology of Thyroid Cancer. *Endocrinol Metab Clin North Am*. 2019 Mar;48(1):23–35.
41. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, *et al*. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2016;26(1):1–133.
42. Lee K, Anastasopoulou C, Chandran C, Cassaro S. Thyroid Cancer [Internet]. *StatPearls*. 2022 [cited 2022 Mar 9]. Available from : <https://pubmed.ncbi.nlm.nih.gov/29083690/>
43. Hishida T, Masai K, Kaseda K, Asakura K, Asamura H. Debulking surgery for malignant tumors: the current status, evidence and future perspectives. *Jpn J Clin Oncol*. 2021 Aug 30;51(9):1349–62.
44. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol*. 2006;154(6):787–803.
45. Yoon BH, Lee Y, Oh HJ, Kim SH, Lee YK. Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. *J Bone Metab*. 2019;26(1):51–60.
46. Park SY, Kim HI, Kim JH, Kim JS, Oh YL, Kim SW, *et al*. Prognostic significance of gross extrathyroidal extension invading only strap muscles in differentiated thyroid carcinoma. *Journal of British Surgery*. 2018;105(9):1155–62.
47. Limaïem F, Kashyap S, Giwa AO. Anaplastic Thyroid Cancer [Internet]. *Stat Pearls*. 2019. [cited 2022 Mar 9]. Available from : <https://www.ncbi.nlm.nih.gov/books/NBK538179/>
48. Edge SB, Edge SB, Cancer AJC on. *AJCC cancer staging manual 8th ed*. Springer New York, NY; 2017.
49. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, *et al*. Overview of the 2022 WHO Classification of Thyroid Neoplasms. *Endocr Pathol*. 2022 Mar 14;33(1):27–63.
50. Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. *Endocrine Related Cancer*. 2014 Sep 5;21(5):T273–83.

51. Schubart JR, Eliassen AH, Schilling A, Goldenberg D. Reproductive Factors and Risk of Thyroid Cancer in Women: An Analysis in the Nurses' Health Study II. *Women's Health Issues*. 2021 Sep;31(5):494–502.
52. Liu J, Xu T, Ma L, Chang W. Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer. *Front Oncol*. 2021 Apr 28;11.
53. Wang J, Yu F, Shang Y, Ping Z, Liu L. Thyroid cancer: incidence and mortality trends in China, 2005–2015. *Endocrine*. 2020 Apr 30;68(1):163–73.
54. Girardi F. Thyroid Carcinoma Pattern Presentation According to Age. *Int Arch Otorhinolaryngol*. 2016 Jul 12;21(01):38–41.
55. Alawadhi R, Matakah A, Alzaabi S, Ahmed N, Alduaij A, Sabri A, et al. Epidemiology and Surgical Characteristics of Thyroid Cancer in United Arab Emirates: Review of 100 Consecutive Patients. *Journal of Diabetes and Endocrine Practice*. 2020 Sep 16;03(02):79–83.
56. Bogović Crnčić T. Risk Factors for Thyroid Cancer: What Do We Know So Far? *Acta Clin Croat*. 2020;
57. Leitzmann MF, Brenner A, Moore SC, Koebnick C, Park Y, Hollenbeck A, et al. Prospective study of body mass index, physical activity and thyroid cancer. *Int J Cancer*. 2010;NA-NA.
58. Gąsior-Perczak D, Pałyga I, Szymonek M, Kowalik A, Waleczyk A, Kopczyński J, et al. The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. *PLoS One*. 2018 Oct 1;13(10):e0204668.
59. Szymańska K, Bosman FT. Thyroid Cancer: Pathology, Genetics, Diagnosis, and Treatment. *Encyclopedia of Cancer*. 2019 Jan 1;471–82.
60. Byun SH, Min C, Choi HG, Hong SJ. Association between Family Histories of Thyroid Cancer and Thyroid Cancer Incidence: A Cross-Sectional Study Using the Korean Genome and Epidemiology Study Data. *Genes (Basel)*. 2020 Sep 3;11(9).
61. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, et al. Prevalence and Distribution of Carcinoma in Patients with Solitary and Multiple Thyroid Nodules on Sonography. *J Clin Endocrinol Metab*. 2006 Sep 1;91(9):3411–7.
62. Ajarma KY, Al-Faouri AF, Al Ruhaibeh MK, Albaidien FA, Nserat RT, Al-Shawabkeh AO, et al. The risk of thyroid carcinoma in multinodular goiter compared to solitary thyroid nodules: A retrospective analysis of 600 patients. *Med J Armed Forces India*. 2020 Jan;76(1):23–9.

63. Li J zhou, Jin Y jun, Liu X, Zhang L yun. [Association between the serum TSH concentration and thyroid cancer incidence]. *Zhonghua Zhong Liu Za Zhi*. 2011 Dec;33(12):921–4.
64. Palo S, Mishra D. Prevalence of malignancy in multinodular goiter and solitary thyroid nodule: a histopathological audit. *Int J Res Med Sci*. 2016;2319–23.
65. Gandolfi PP, Frisina A, Raffa M, Renda F, Rocchetti O, Ruggeri C, et al. The incidence of thyroid carcinoma in multinodular goiter: retrospective analysis. *Acta Biomed*. 2004 Aug;75(2):114–7.
66. Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi A. Malignancy in solitary thyroid nodule: A clinicoradiopathological evaluation. *Indian J Endocrinol Metab*. 2015;19(4):498.
67. Smith-Bindman R, Lebda P, Feldstein VA, Sellami D, Goldstein RB, Brasic N, et al. Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. *JAMA Intern Med*. 2013 Oct 28;173(19):1788–96.
68. Albuja-Cruz MB, Goldfarb M, Gondek SS, Allan BJ, Lew JI. Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. *Journal of Surgical Research*. 2013 May;181(1):6–10.
69. Megwalu UC. Risk of Malignancy in Thyroid Nodules 4 cm or Larger. *Endocrinology and Metabolism*. 2017;32(1):77.
70. Cavallo A, Johnson DN, White MG, Siddiqui S, Antic T, Mathew M, et al. Thyroid Nodule Size at Ultrasound as a Predictor of Malignancy and Final Pathologic Size. *Thyroid*. 2017 May;27(5):641–50.
71. Bohacek L, Milas M, Mitchell J, Siperstein A, Berber E. Diagnostic Accuracy of Surgeon-Performed Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules. *Ann Surg Oncol*. 2012 Jan 2;19(1):45–51.
72. Henrichsen TL, Reading CC, Charboneau JW, Donovan DJ, Sebo TJ, Hay ID. Cystic change in thyroid carcinoma: Prevalence and estimated volume in 360 carcinomas. *Journal of Clinical Ultrasound*. 2010 Sep 3;38(7):361–6.
73. Koike E. Ultrasonographic Characteristics of Thyroid Nodules. *Archives of Surgery*. 2001 Mar 1;136(3):334.
74. Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, et al. A Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973–2004. *Thyroid*. 2009 Oct;19(10):1061–6.
75. McHenry CR, Phitayakorn R. Follicular Adenoma and Carcinoma of the Thyroid Gland. *Oncologist*. 2011 May 1;16(5):585–93.

76. Kitahara CM, Sosa JA, Shiels MS. Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017. *J Clin Endocrinol Metab.* 2020 Dec 1;105(12):e4823–30.
77. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. *JAMA.* 2017 Apr 4;317(13):1338.
78. Hartl DM, Guerlain J, Breuskin I, Hadoux J, Baudin E, Al Ghuzlan A, *et al.* Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer. *Cancers (Basel).* 2020 Nov 6;12(11):3282.
79. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, *et al.* Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. *Ann Surg.* 2014 Oct;260(4):601–7.
80. Kuba S, Yamanouchi K, Hayashida N, Maeda S, Adachi T, Sakimura C, *et al.* Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study. *International Journal of Surgery.* 2017 Feb;38:143–8.

